Association between the CYP3A5 genotype and blood pressure

Hypertension

Volumn 45, Issue 2, 2005, Pages 294-298

  Ho, Herbert ^a   Pinto, Amar ^a   Hall, Stephen D ^a   Flockhart, David A ^a   Li, Lang ^a   Skaar, Todd C ^a   Cadman, Peter ^b   O'Connor, Daniel T ^b   Wagner, Urban ^a   Fineberg, Naomi S ^a   Weinberger, Myron H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

Blood pressure; Cytochrome p450; Genetics; Polymorphism

Indexed keywords

CARBOHYDRATE; CYTOCHROME P450 3A5;

AFRICAN AMERICAN; ALLELE; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD VESSEL COMPLIANCE; CARBOHYDRATE INTOLERANCE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; EUROPEAN AMERICAN; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; SYSTOLE;

EID: 19944431766     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000151361.31736.96     Document Type: Article

References (31)

1. Fingerhut LA, Wilson RW, Feldman JJ. Health and disease in the United States. Annu Rev Public Health. 1980;1:1-36.
2. Arias E, Anderson RN, Kung HC, Murphy SL, Kochanek KD. Deaths: final data for 2001. Natl Vital Stat Rep. 2003;52:1-115.
3. Arias E, MacDorman MF, Strobino DM, Guyer B. Annual summary of vital statistics-2002. Pediatrics. 2003;112:1215-1230.
4. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep. 2001;49:1-113.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285: 2486-2497.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc. 2003;289:2560-2572.
7. Timberlake DS, O'Connor DT, Parmer RJ. Molecular genetics of essential hypertension: recent results and emerging strategies. Curr Opin Nephrol Hypertens. 2001;10:71-79.
8. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Delivery Rev. 2002;54:1271-1294.
9. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004;5:243-272.
10. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003;95: 1297-1300.
11. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, Wright JT Jr, Guzelian PS. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther. 1992;51: 18-23.
12. Ghosh S, Grogan WM, Basu A, Watlington C. Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. Biochim Biophys Acta. 1993;1182:152-156.
13. Ghosh SS, Basu AK, Ghosh S, Hagley R, Kramer L, Schuetz J, Grogan WM, Guzelian P, Watlington CO. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem Pharmacol. 1995;50:49-54.
14. Watlington CO, Kramer LB, Schuetz EG, Zilai J, Grogan WM, Guzelian P, Gizek F, Schoolwerth AC. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol. 1992;262:F927-F931.
15. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996;50:52-59.
16. Haehner BD, Strong M, Hamman MA, Hall SD. The variable kinetics of cytochrome P450 3A isoforms in the 6β-hydroxylation of cortisol. Pharmacologist. 1997;39:21.
17. Duncan RL, Grogan WM, Kramer LB, Watlington CO. Corticosterone's metabolite is an agonist for Na+ transport stimulation in A6 cells. Am J Physiol. 1988;255:F736-F748.
18. Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP. A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol. 1998;274:C1245-C1252.
19. Grogan WM, Fidelman ML, Newton DE, Duncan RL, Watlington CO. A corticosterone metabolite produced by A6 (toad kidney) cells in culture: identification and effects on Na+ transport. Endocrinology. 1985;116: 1189-1194.
20. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986;8:II127-134.
21. Weinberger MH, Fineberg NS, Fineberg SE. The influence of blood pressure and carbohydrate tolerance on vascular compliance in humans. Am J Hypertens. 2002;15:678-682.
22. Weinberger MH, Fineberg NS, Fineberg SE. Effects of age, race, gender, blood pressure, and estrogen on arterial compliance. Am J Hypertens. 2002;15:358-363.
23. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37:429-432.
24. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab. 2000;85: 4426-4433.
25. Hiratsuka M, Agatsuma Y, Omori F, Narahara K, Inoue T, Kishikawa Y, Mizugaki M. High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5′ nuclease chain reaction assay. Biol Pharm Bull. 2000;23:1131-1135.
26. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, Mizugaki M. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 2002;58:417-421.
27. Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA. Human sympathetic activation by [alpha]2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin PharmacolTher. 2004;76:139-153.
28. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension. 2003; 41:207-210.
29. Kornel L, Miyabo S, Saito Z, Cha RW, Wu FT. Corticosteroids in human blood. VIII. Cortisol metabolites in plasma of normotensive subjects and patients with essential hypertension. J Clin Endocrinol Metab. 1975;40: 949-958.
30. Blaustein MP, Grim CE. The pathogenesis of hypertension: black-white differences. Cardiovasc Clin. 1991;21:97-114.
31. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002;19:527-534.